We recently demonstrated that classical IL-6 signaling by donor T cells is the predominant pathway in GVHD pathogenesis (18), and inhibition of IL-6 signaling with the IL-6R monoclonal antibody tocilizumab has shown activity in the prevention of acute GVHD in clinical studies (19–21). Here, IL6 is linked to acute graft versus host disease.